The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Open accessAbstract
Diffuse large B cell lymphomas (DLBCLs) arise from proliferating B cells transiting different stages of the germinal center reaction. In activated B cell DLBCLs (ABC-DLBCLs), a class of DLBCLs that respond poorly to current therapies, chromosomal translocations and amplification lead to constitutive expression of the B cell lymphoma 6 (BCL6) oncogene. The role of BCL6 in maintaining these lymphomas has not been investigated. Here, we designed small-molecule inhibitors that display higher affinity for BCL6 than its endogenous corepressor ligands to evaluate their therapeutic efficacy for targeting ABC-DLBCL. We used an in silico drug design functional-group mapping approach called SILCS to create a specific BCL6 inhibitor called FX1 that has 10-fold greater potency than endogenous corepressors and binds an essential region of the BCL6 lateral groove. FX1 disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, and mimicked the phenotype of mice engineered to express BCL6 with corepressor binding site mutations. Low doses of FX1 induced regression of established tumors in mice bearing DLBCL xenografts. Furthermore, FX1 suppressed ABC-DLBCL cells in vitro and in vivo, as well as primary human ABC-DLBCL specimens ex vivo. These findings indicate that ABC-DLBCL is a BCL6-dependent disease that can be targeted by rationally designed inhibitors that exceed the binding affinity of natural BCL6 ligands.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several peptide and small molecule inhibitors targeting BCL6 have shown efficacy in vivo, but only at high concentrations, which has limited their translation into clinical therapeutic agents13,14.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [14]
In the citing paper
“BCL6 is a promising drug target for non-Hodgkin lymphomas including diffuse large B cell lymphoma (DLBCL)13,14 and follicular lymphoma15.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Hans, C. P. (2003) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 4,270
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 4,196
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 2,002
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B. A., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,353
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,205
Protein-binding assays in biological liquids using microscale thermophoresis
Wienken, C. J., Baaske, P., Rothbauer, U., Braun, D., & Duhr, S. (2010) · Nature Communications · doi:10.1038/ncomms1093 · Cited by 1,145
Wright, G. W., Tan, B. K., Rosenwald, A., Hurt, E. H., Wiestner, A. U., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,055
Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K. K., Klasa, R. J., Macpherson, N. A., O'Reilly, S., Spinelli, J. J., Sutherland, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.137 · Cited by 985
Cited by
Sorted by citations
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David‐Cordonnier, M. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 359
Small-molecule-induced polymerization triggers degradation of BCL6
Słabicki, M., Yoon, H., Koeppel, J., Nitsch, L., Roy Burman, S. S., Di Genua, C., Donovan, K. A., Sperling, A. S., Hunkeler, M., Tsai, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2925-1 · Cited by 270
Béguelin, W., Teater, M., Gearhart, M. D., Calvo Fernández, M. T., Goldstein, R. L., Cárdenas, M. G., Hatzi, K., Rosen, M., Shen, H., Corcoran, C. M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.006 · Cited by 254
Self-citationChemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207
Metadata
- Authors
- Cardenas, M. G., Yu, W., Beguelin, W., Teater, M. R., Geng, H., Goldstein, R. L., Oswald, E., Hatzi, K., Yang, S.-N., Cohen, J., Shaknovich, R., Vanommeslaeghe, K., Cheng, H., Liang, D., Cho, H. J., Abbott, J., Tam, W., Du, W., Leonard, J. P., Elemento, O., Cerchietti, L., Cierpicki, T., Xue, F., MacKerell, A. D., & Melnick, A. M.
- Affiliations
- University of Maryland, Baltimore (US)
- University of California, San Francisco (US)
- Weill Cornell Medicine (US)
- University of Michigan (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-02
- Volume
- 126
- Issue
- 9
- Pages
- 3351-3362
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5004937
- OpenAlex
- W2505733981
- Cited by
- 176
- References
- 40
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 19 · 2023: 14 · 2022: 25 · 2021: 16 · 2020: 21 · 2019: 18 · 2018: 20 · 2017: 16 · 2016: 5
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Samuel Waxman Cancer Research Foundation
- Leukemia and Lymphoma Society
- Weill Cornell Medical College
- National Cancer Institute (R01CA194547)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- BCL6, small molecule inhibitors, germinal center, chromosomal translocation, lymphoma treatment
- MeSH terms
- Animals, Antineoplastic Agents, Doxorubicin, Drug Screening Assays, Antitumor, Humans, Indoles, Ligands, Male, Neoplasm Transplantation, Magnetic Resonance Spectroscopy, Protein Binding, Translocation, Genetic, Drug Design, Gene Expression Regulation, Neoplastic, Lymphoma, Large B-Cell, Diffuse, Mice, SCID, Thiazolidinediones, Cell Line, Tumor, Mice, Proto-Oncogene Proteins c-bcl-6, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
